Impact Factor 4.259 | CiteScore 4.30
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Microbiol. | doi: 10.3389/fmicb.2019.01690

Bacterial proteinaceous compounds with multiple activities toward cancers and microbial infection

  • 1Universidade Católica de Brasília, Brazil
  • 2Dom Bosco Catholic University, Brazil
  • 3Pos-Graduação em Ciencias Genomicas e Biotecnologia, Universidade Católica de Brasília, Brazil

In recent decades, cancer and multidrug resistance have become a worldwide problem, resulting in high morbidity and mortality. Some infectious agents like Streptococcus pneumoniae, Stomatococcus mucilaginous, Staphylococcus spp., Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa, Candida spp, Helicobacter pylori, hepatitis B and C, and human papillomaviruses (HPV) have been associated with the development of cancer. Chemotherapy, radiotherapy and antibiotics are the conventional treatment for cancer and infectious disease. This treatment causes damage in healthy cells and tissues, and usually triggers systemic side-effects, as well as drug resistance. Therefore, the search for new treatments is urgent, in order to improve efficacy and also reduce side-effects. Proteins and peptides originating from bacteria can thus be a promising alternative to conventional treatments used nowadays against cancer and infectious disease. These molecules have demonstrated specific activity against cancer cells and bacterial infection; indeed, proteins and peptides can be considered as future antimicrobial and anticancer drugs. In this context, this review will focus on the desirable characteristics of proteins and peptides from bacterial sources that demonstrated activity against microbial infections and cancer, as well as their efficacy in vitro and in vivo.

Keywords: antimicrobial, anticancer, bacteriocin, protein, peptides.

Received: 14 Apr 2019; Accepted: 09 Jul 2019.

Edited by:

Bingyun Li, West Virginia University, United States

Reviewed by:

Ramya Viswanathan, National Institutes of Health (NIH), United States
Hai Liang, National Institutes of Health (NIH), United States  

Copyright: © 2019 Rodrigues, Silva, Buccini, Duque, Dias and Franco. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Octavio L. Franco, Universidade Católica de Brasília, Pos-Graduação em Ciencias Genomicas e Biotecnologia, Brasília, 71837-360, Distrito Federal, Brazil,